Janus Feasibility Study

Completed · Not applicable

Conditions studied: Sleep Apnea Syndromes

In brief

The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.

Key facts

Study ID

NCT03985527

Run by

Respicardia, Inc.

People needed

29

Starts

2020-01-09

Expected to finish

2025-12-12

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is at least 18 years old
• Subject with moderate to severe central sleep apnea is undergoing a de novo commercial remedē® System implant procedure or other de novo transvenous cardiac implantable device procedure including a pacemaker or an implantable cardiac defibrillator
• Subject is willing and able to give informed consent

You may not qualify if…

• Subject is unable or unwilling to participate with study procedures or in the investigator's opinion is medically unstable for the procedure (Medically unstable is defined as when a patient is expected to have worsening health status if additional procedure time is needed)
• Subject is pregnant or planning to become pregnant (all women with childbearing potential must have a negative pregnancy test within 7 days prior to the implant)
• Subject is known to be allergic to radio opaque dye which cannot safely be pre-treated per the investigator
• Subject has body mass index (BMI) > 40 kg/m2 at the time of implant
• Subject has had prior neck surgery
• Previous or currently implanted upper airway stimulation device
• Subject has had prior oral cavity surgery that may interfere with breathing
• Subject has significant upper airway-related anatomic anomaly
• Subject is enrolled in concurrent study that may confound the results of this study
• Subject is taking muscle relaxant medication unless approved by the site implanter and ZOLL Respicardia clinical staff
• Subject has evidence of nerve weakness/paresis/paralysis or a neurologic disorder that involves the tongue

Where it is running

• Novant Health Forsyth Medical Center — Winston-Salem, North Carolina, United States
• The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• Bryn Mawr Medical Specialists Association — Bryn Mawr, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.